title: Phenolic antioxidants trolox and caffeic acid modulate the oxidized LDL-induced EGF-receptor activation.
abstract: Oxidized low density lipoproteins (oxLDL) are thought to play a major role in atherosclerosis. OxLDL act in part through alteration of intracellular signalling pathways in cells of the vascular wall. We recently reported that the EGF receptor (EGFR) signalling pathway is activated by lipid peroxidation products (among them 4-hydroxynonenal, 4-HNE) contained in oxLDL. The use of phenolic antioxidants, such as trolox, alpha-tocopherol, caffeic acid and tyrphostins A-25, A-46 or A-1478, showed that the oxLDL-induced EGFR activation is constituted by two separate components, the first (early) one being antioxidant-insensitive, the second (late) being antioxidant-sensitive. 4-HNE derivatization of EGFR and EGFR activation induced by exogenous 4-HNE, suggest that the early (0.5 - 3 h) component of oxLDL-induced EGFR activation is mediated (at least in part) by 4-HNE (and possibly by other oxidized lipids). This early component is antioxidant-insensitive. The second component (4 - 5 h) of the oxLDL-induced EGFR activation is antioxidant-sensitive, since it is blocked by antioxidants such as trolox, caffeic acid or PDTC, which act by blocking the cellular oxidative stress (H(2)O(2) generation) evoked by oxLDL. Conversely, exogenous H(2)O(2) induced EGFR autophosphorylation (thus mimicking the second component) and was also inhibited by antioxidants. This effect is mediated in part through inhibition by oxidative stress of protein tyrosine phosphatases involved in EGFR dephosphorylation.
authors: INSERM U.466, Biochemistry Department, University Paul Sabatier, Toulouse, France.
authors: N
authors: N
authors: Vacaresse
authors: O
authors: O
authors: Vieira
authors: F
authors: F
authors: Robbesyn
authors: G
authors: G
authors: Jürgens
authors: R
authors: R
authors: Salvayre
authors: A
authors: A
authors: Negre-Salvayre
mesh_terms: D000447:Aldehydes / Q000494:pharmacology; D000975:Antioxidants / Q000494:pharmacology*; D001711:Biotransformation / Q000187:drug effects; D015153:Blotting, Western; D002109:Caffeic Acids / Q000494:pharmacology*; D002460:Cell Line; D002839:Chromans / Q000494:pharmacology*; D003432:Cross-Linking Reagents / Q000494:pharmacology; D066246:ErbB Receptors / Q000187:drug effects*; D006801:Humans; D006861:Hydrogen Peroxide / Q000494:pharmacology; D008077:Lipoproteins, LDL / Q000037:antagonists & inhibitors* / Q000302:isolation & purification / Q000494:pharmacology; D010084:Oxidation-Reduction; D010766:Phosphorylation; D011233:Precipitin Tests; D017027:Protein Tyrosine Phosphatases / Q000037:antagonists & inhibitors; D011505:Protein-Tyrosine Kinases / Q000378:metabolism
chemical_list: D000447:Aldehydes; D000975:Antioxidants; D002109:Caffeic Acids; D002839:Chromans; D003432:Cross-Linking Reagents; D008077:Lipoproteins, LDL; D006861:Hydrogen Peroxide; D066246:ErbB Receptors; D011505:Protein-Tyrosine Kinases; D017027:Protein Tyrosine Phosphatases; C027576:4-hydroxy-2-nonenal; C010643:6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid; C040048:caffeic acid